Literature DB >> 12621057

The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2).

Juana M Del Valle1, Pablo Engel, Margarita Martín.   

Abstract

CD229 (Ly9) is a cell surface receptor selectively expressed on T and B lymphocytes, and it belongs to the CD150 receptor family. Like other receptors of this family, CD229 interacts with SAP/SH2D1a protein, mutation of which is responsible for the fatal X-linked lymphoproliferative disease. Receptors of the CD150 family function as costimulatory molecules, regulating cytokine production and cytotoxicity. Thus, their signaling and regulation in lymphocytes may be critical to an understanding of the pathogenesis of the X-linked lymphoproliferative disease. Here we show that CD229 interacts with the mu(2) chain of the AP-2 adaptor complex that links transmembrane proteins to clathrin-coated pits. CD229 was the only member of the CD150 family associated with AP-2. We also show that the mu(2) chain interacts with the Y(470)EKL motif of CD229. The integrity of this site was necessary for CD229 internalization, but it was not involved in SAP recruitment. Moreover, CD229 binds to the AP-2 complex in T and B cell lines, and it is internalized rapidly from the cell surface on T cells after antibody ligation. In contrast, cross-linking of CD229 receptors with intact antibody inhibited CD229 internalization on B cells. However, when F(ab')(2) antibodies were used, CD229 internalization was similar on T and B cells, suggesting that Fcgamma receptors control CD229 cell surface expression. Furthermore, CD229 was regulated by T cell receptor and B cell receptor signaling because coligation with antibodies against anti-CD3 and anti-IgM increased the rate of CD229 endocytosis. These data suggest that CD229 cell surface expression on lymphocytes surface is strongly and differentially regulated within the CD150 family members.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12621057     DOI: 10.1074/jbc.M301569200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  Novel anti-myeloma immunotherapies targeting the SLAM family of receptors.

Authors:  Sabarinath Venniyil Radhakrishnan; Neelam Bhardwaj; Tim Luetkens; Djordje Atanackovic
Journal:  Oncoimmunology       Date:  2017-03-28       Impact factor: 8.110

2.  CD84 negatively regulates IgE high-affinity receptor signaling in human mast cells.

Authors:  Damiana Álvarez-Errico; Irene Oliver-Vila; Erola Ainsua-Enrich; Alasdair M Gilfillan; César Picado; Joan Sayós; Margarita Martín
Journal:  J Immunol       Date:  2011-11-07       Impact factor: 5.422

Review 3.  SLAM family receptors and the SLAM-associated protein (SAP) modulate T cell functions.

Authors:  Cynthia Detre; Marton Keszei; Xavier Romero; George C Tsokos; Cox Terhorst
Journal:  Semin Immunopathol       Date:  2010-02-10       Impact factor: 9.623

Review 4.  Endocytosis and intracellular trafficking of human natural killer cell receptors.

Authors:  Madhan Masilamani; Giovanna Peruzzi; Francisco Borrego; John E Coligan
Journal:  Traffic       Date:  2009-08-05       Impact factor: 6.215

5.  Simultaneous TCR and CD244 signals induce dynamic downmodulation of CD244 on human antiviral T cells.

Authors:  Yovana Pacheco; Anna P McLean; Janine Rohrbach; Filippos Porichis; Daniel E Kaufmann; Daniel G Kavanagh
Journal:  J Immunol       Date:  2013-08-02       Impact factor: 5.422

Review 6.  SLAMF6 in health and disease: Implications for therapeutic targeting.

Authors:  Burcu Yigit; Ninghai Wang; Roland W Herzog; Cox Terhorst
Journal:  Clin Immunol       Date:  2018-10-23       Impact factor: 3.969

7.  A Peptide Mimetic of 5-Acetylneuraminic Acid-Galactose Binds with High Avidity to Siglecs and NKG2D.

Authors:  Laura L Eggink; Georgios A Spyroulias; Norman G Jones; Carl V Hanson; J Kenneth Hoober
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

8.  The expression of the hepatocyte SLAMF3 (CD229) receptor enhances the hepatitis C virus infection.

Authors:  Flora Cartier; Ingrid Marcq; Florian Douam; Christèle Ossart; Aline Regnier; Véronique Debuysscher; Dimitri Lavillette; Hicham Bouhlal
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

Review 9.  Signaling lymphocytic activation molecules Slam and cancers: friends or foes?

Authors:  Gregory Fouquet; Ingrid Marcq; Véronique Debuysscher; Jagadeesh Bayry; Amrathlal Rabbind Singh; Abderrahmane Bengrine; Eric Nguyen-Khac; Mickael Naassila; Hicham Bouhlal
Journal:  Oncotarget       Date:  2018-02-26

10.  Identification of SLAMF3 (CD229) as an inhibitor of hepatocellular carcinoma cell proliferation and tumour progression.

Authors:  Ingrid Marcq; Rémy Nyga; Flora Cartier; Rabbind Singh Amrathlal; Christèle Ossart; Hakim Ouled-Haddou; Hussein Ghamlouch; Antoine Galmiche; Denis Chatelain; Luciane Lamotte; Véronique Debuysscher; Vincent Fuentes; Eric Nguyen-Khac; Jean-Marc Regimbeau; Jean-Pierre Marolleau; Sylvain Latour; Hicham Bouhlal
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.